Physician profile
Bruce M Dow
NPI 1275615684
$5,161.52
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,385 · 2020: $363 · 2021: $1,208 · 2022: $1,519 · 2023: $664 · 2024: $21.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $685.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $882.76 | 2019-2023 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $854.86 | 2020-2024 | Caplyta |
| Alkermes, INC. | $616.94 | 2019-2023 | Aristada, Lybalvi |
| Abbvie INC. | $566.85 | 2021-2023 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $548.44 | 2019-2023 | Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $461.93 | 2019-2023 | Austedo |
| Sunovion Pharmaceuticals INC. | $289.21 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $285.71 | 2019-2023 | Ingrezza |
| Allergan, INC. | $272.06 | 2019-2020 | |
| Corium, LLC | $133.84 | 2022-2023 | Azstarys |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $91.51 | 2019 | |
| Indivior INC. | $67.35 | 2023 | Perseris |
| Noven Pharmaceuticals, INC. | $43.19 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $30.30 | 2019 | |
| Noven Therapeutics, LLC | $16.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Dow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.